Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Ku

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Lancet (London, England)|November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialJeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Haematologica|February 23, 2023
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma AllianceAllison Barraclough, James T England, Diego Villa, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Lancet (London, England)|November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialJeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Haematologica|February 23, 2023
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma AllianceAllison Barraclough, James T England, Diego Villa, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Pageof 7